General Information of This Target
Target ID
PATR0VPYPS
Target Name
Glucocorticoid receptor (NR3C1)
Gene Name
NR3C1
Gene ID
2908
Synonym
GRL; Nuclear receptor subfamily 3 group C member 1
Sequence
MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRR
LLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLK
LLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGN
VKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGN
SNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTV
YCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVG
SENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKL
CLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRK
CLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIE
PEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSW
MFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSY
EEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTK
LLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK

    Click to Show/Hide
Family
the nuclear hormone receptor family
Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling. Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth.[Isoform Alpha]: Has transcriptional activation and repression activity. Mediates glucocorticoid-induced apoptosis. Promotes accurate chromosome segregation during mitosis. May act as a tumor suppressor. May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic gene expression.[Isoform Beta]: Acts as a dominant negative inhibitor of isoform Alpha. Has intrinsic transcriptional activity independent of isoform Alpha when both isoforms are coexpressed. Loses this transcription modulator function on its own. Has no hormone-binding activity. May play a role in controlling glucose metabolism by maintaining insulin sensitivity. Reduces hepatic gluconeogenesis through down-regulation of PEPCK in an isoform Alpha-dependent manner. Directly regulates STAT1 expression in isoform Alpha-independent manner.[Isoform Alpha-2]: Has lower transcriptional activation activity than isoform Alpha. Exerts a dominant negative effect on isoform Alpha trans-repression mechanism.[Isoform GR-P]: Increases activity of isoform Alpha.

    Click to Show/Hide
Uniprot Entry
GCR_HUMAN
HGNC ID
HGNC:7978
KEGG ID
hsa:2908
Full List of The ADC Related to This Target
Phase 2
Click To Hide/Show 2 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
ABBV-3373
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 17
MP-Ala-Ala
[1]
ABBV-154
Adalimumab
TNF
Glucocorticoid receptor modulator
Formyl-Gly-Glu
[2]
Phase 1
Click To Hide/Show 1 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
ABBV-319
Anti-CD19 ABBV319 IgG1 mAb
CD19
Proprietary GRM agonist
Formyl-Ala-Ala
[3]
Clinical candidate
Click To Hide/Show 2 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
CD70-glucocorticoid ADC
Undisclosed
CD70
Fluticasone propionate
Pyrophosphate linker
[4]
Cymac-001
Undisclosed
CD163
Dexamethasone
Undisclosed
[5]
Investigative
Click To Hide/Show 33 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
Anti-TNF ADC 121
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 17
MP-Ala-Ala
[6]
Anti-TNF ADC 126
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 20
MP-Ala-Ala
[6]
Anti-TNF ADC 127
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 25
MP-Ala-Ala
[6]
Anti-TNF ADC 128
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 26
MP-Ala-Ala
[6]
Anti-TNF ADC 129
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 30
MP-Ala-Ala
[6]
Anti-TNF ADC 131
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 31
MP-Ala-Ala
[6]
Anti-TNF ADC 134
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 64
MP-Ala-Ala
[6]
Anti-TNF ADC 104
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 5
MP-Ala-Ala
[6]
Anti-TNF ADC 105
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 16
MP-Ala-Ala
[6]
Anti-TNF ADC 106
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 17
MP-Ala-Ala
[6]
Anti-TNF ADC 107
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 18
MP-Ala-Ala
[6]
Anti-TNF ADC 108
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 19
MP-Ala-Ala
[6]
Anti-TNF ADC 109
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 20
MP-Ala-Ala
[6]
Anti-TNF ADC 110
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 22
MP-Ala-Ala
[6]
Anti-TNF ADC 111
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 23
MP-Ala-Ala
[6]
Anti-TNF ADC 112
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 24
MP-Ala-Ala
[6]
Anti-TNF ADC 113
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 25
MP-Ala-Ala
[6]
Anti-TNF ADC 114
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 26
MP-Ala-Ala
[6]
Anti-TNF ADC 115
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 30
MP-Ala-Ala
[6]
Anti-TNF ADC 116
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 31
MP-Ala-Ala
[6]
Anti-TNF ADC 117
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 33
MP-Ala-Ala
[6]
Anti-TNF ADC 118
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 61
MP-Ala-Ala
[6]
Anti-TNF ADC 119
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 5
MP-Ala-Ala
[6]
Anti-TNF ADC 120
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 5
MP-Ala-Ala
[6]
Anti-TNF ADC 123
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 19
MP-Ala-Ala
[6]
Anti-TNF ADC 124
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 19
MP-Ala-Ala
[6]
Anti-TNF ADC 125
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 20
MP-Ala-Ala
[6]
Anti-TNF ADC 130
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 31
MP-Ala-Ala
[6]
Anti-TNF ADC 132
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 32
MP-Ala-Ala
[6]
Anti-TNF ADC 133
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 32
MP-Ala-Ala
[6]
Anti-TNF ADC 135
Anti-TNF mAb alpha-TNF
TNFRSF1A
GRM cpd 63
MP-Ala-Ala
[6]
Anti-PRLR-Ab-LP2-P12
Anti-PRLR mAb
PRLR
Budesonide derivative P12
DIBAC-suc-PEG4-Val-Cit-PAB
[7]
Anti-PRLR-Ab-LP1-P3
Anti-PRLR mAb
PRLR
Budesonide derivative P3
DIBAC-suc-PEG4-Val-Cit-PAB
[7]
References
Ref 1 Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial. Arthritis Rheumatol. 2023 Jun;75(6):879-889.
Ref 2 Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA); NCT04888585,
Ref 3 A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug Conjugate Composed of a CD19 Antibody Linked to a Potent Proprietary Glucocorticoid Receptor Modulator, in Patients with Relapsed or Refractory B-Cell Malignancies. Blood (2022) 140 (Supplement 1): 3746-3747. doi: 10.1182/blood-2022-166809.
Ref 4 Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates. J Am Chem Soc. 2016 Feb 3;138(4):1430-45. doi: 10.1021/jacs.5b12547. Epub 2016 Jan 25.
Ref 5 Introduction to basic information on ADC drug CYMAC-001 (ANTI-CD163-DEXAMETHASONE ADC).
Ref 6 Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate. J Med Chem. 2022 Dec 8;65(23):15893-15934.
Ref 7 Development of Novel Glucocorticoids for Use in Antibody-Drug Conjugates for the Treatment of Inflammatory Diseases. J Med Chem. 2021 Aug 26;64(16):11958-11971. doi: 10.1021/acs.jmedchem.1c00541. Epub 2021 Aug 11.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.